|Day Low/High||4.15 / 4.39|
|52 Wk Low/High||3.35 / 11.65|
The milestone approval of Epidiolex bodes well for cannabis-based drug stocks GW Pharma, Nemus, Zynerba and Insys.
While cannabis remains illegal on a federal level, these seven names are making early inroads into the growing industry.
The clinical-stage biopharmaceutical firm said Oct. 16 it has priced an underwritten public offering of five million shares at $16 apiece.
Donald Trump was not the only big winner on Election Day. The cannabis industry got a spark as well.
From green technology to medicinal marijuana, investors will be surprised at which IPO looks good. Francis Gaskins gives details.